SHR Reference Model Version 1.0.0
shr.oncology

Entry Element MammaprintRecurrenceScore

Documentation:

Breast cancer genomic signature assay for 10-year risk of distant recurrence score calculated by Mammaprint.

In the United States, MammaPrint can only be used on cancers that are stage I or stage II, invasive, smaller than 5 centimeters, and estrogen-receptor-positive or -negative. Scores range from -1.0 to +1.0, with scores less than 0 indicating high risk, and scores greater than 0 indicating low risk.

The is currently no LOINC code for Mammaprint test.

Ancestors: